Vicore Pharma Holding AB
VCRE - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$276.83M
Close$
$2.48
75.2% downside
Current Fair Value
75.2% downsideOvervalued by 75.2% based on the discounted cash flow analysis.
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $276.83 Million |
|---|---|
| Enterprise Value | - |
| Earnings per Share | $-2.2 |
| Beta | 0.15 |
| Outstanding Shares | 28,008,626 |
Return
| Return on Equity | NaN% |
|---|---|
| Return on Assets | NaN% |
| Return on Invested Capital | NaN% |
Valuation & Multiples
| P/E Ratio | -5.05 |
|---|---|
| PEG | 5.79 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | - |
| Enterprise Value to Net Income | - |
| Total Debt to Enterprise | - |
| Debt to Equity | - |
Revenue Sources
No data
Last Earnings Call
Report Date
August 21, 2026
EPS Estimate
$-0.42
Consensus analyst estimateRevenue Estimate
$477,000
Consensus analyst estimateNext Earnings Call
Expected Date
February 25, 2027
EPS Estimate
$-0.53
Consensus analyst estimateRevenue Estimate
$106,813
Consensus analyst estimateInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
About Vicore Pharma Holding AB
37 employees
CEO: Ahmed Mousa
Vicore Pharma Holding AB is a pharmaceutical company, which engages in the development of drugs with focus on interstitial lung diseases and related indications. Its drug development programs include VP01, VP02, VP03, and VP04. The compa...